Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics President and CEO Carole Ben-Maimon reported equity awards dated January 26, 2026. She received 100,100 shares of Common Stock for no cash cost, structured as restricted stock units that each convert into one share upon settlement.
She was also granted a stock option for 600,600 shares of Common Stock at an exercise price of $3.60 per share. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to her continued service. After these grants, she directly holds 368,276 shares of Common Stock and 600,600 stock options, while several irrevocable family trusts for which she serves as trustee each hold 31,155 or 31,156 shares; she disclaims beneficial ownership of those trust shares except to any pecuniary interest.
Larimar Therapeutics reported an equity compensation grant to its Chief Financial Officer, Michael Celano. On January 26, 2026, he received 37,604 shares of Common Stock at a price of $0.00 per share, represented by restricted stock units that each convert into one share upon settlement. Following this award, he beneficially owned 215,785 shares of Common Stock directly. The same day, he was also granted a stock option covering 225,622 shares of Common Stock with a $3.6 exercise price per share. This option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, contingent on his continued service, and expires on January 26, 2036.
Larimar Therapeutics, Inc. entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, where the investor will exchange 2,500,000 shares of Larimar common stock for 250,000 shares of Series A convertible preferred stock. Each preferred share is convertible into 10 common shares, but the preferred stock generally carries no voting rights and shares in liquidation proceeds on the same basis as common stock, subject to its ranking terms. In connection with this exchange, Larimar amended the existing designation to increase authorized Series A preferred shares from 250,000 to 500,000. The exchange is expected to close on January 23, 2026, and the preferred shares will be issued without registration under the Securities Act in reliance on Section 3(a)(9).
Larimar Therapeutics, Inc. reported that it had approximately $136.9 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure was shared in an updated slide presentation posted on the company’s website and is described as unaudited, preliminary and prepared by management, meaning it could change once the company completes its quarter- and year-end financial closing processes.
The company notes that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed procedures on this preliminary cash figure and provides no assurance on it. Larimar also posted an updated corporate presentation, attached as Exhibit 99.1, which its representatives may use in meetings with investors, analysts and other parties.
Larimar Therapeutics entered an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, under which the stockholder exchanged 2,500,000 shares of common stock for 250,000 shares of newly designated Series A convertible preferred stock.
Each preferred share is convertible into 10 common shares, subject to a 9.99% beneficial ownership Conversion Blocker, which holders may increase to 19.99% upon 60 days’ notice. The Preferred Stock generally has no voting rights other than as required by law and to approve changes to its terms, participates pari passu with common stock in dividends and liquidation on an as-converted basis, and was issued in reliance on the Section 3(a)(9) exemption from Securities Act registration.
Larimar Therapeutics (LRMR) filed an 8-K announcing an updated corporate presentation posted to its website and furnished as Exhibit 99.1, dated November 10, 2025. The company plans to use the slide deck in meetings with investors, analysts, and other stakeholders.
This is an informational update intended to support outreach and communication. The filing also lists the company’s common stock on the Nasdaq Global Market under the symbol LRMR.
Larimar Therapeutics (LRMR) reported Q3 2025 results highlighted by increased R&D investment as it advances nomlabofusp for Friedreich’s ataxia. The company posted a net loss of $47.7 million, driven by research and development expense of $44.9 million and general and administrative expense of $4.6 million. Cash, cash equivalents and marketable securities totaled $175.4 million as of September 30, 2025, supported by $65.0 million of net proceeds from a July 31 underwritten offering.
Management reiterated its regulatory path: participation in FDA’s START pilot, FDA feedback that skin frataxin (FXN) concentration may be considered a reasonably likely surrogate endpoint subject to future review, and BLA safety database parameters. The company targets a BLA submission for accelerated approval in Q2 2026 and plans a regulatory and study status update in Q1 2026. In its open-label study, 65 participants have received at least one dose, with directional improvements across clinical outcomes and FXN levels; 7 anaphylaxis events occurred early in dosing and the firm is implementing a modified starting regimen agreed with FDA. Shares outstanding were 85,590,392 as of November 3, 2025.
Larimar Therapeutics, Inc. filed an 8-K announcing it furnished a press release with financial results and operational highlights for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act.
Larimar Therapeutics (LRMR) reported that it posted an updated corporate slide presentation on its website. The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and incorporated by reference.
Company representatives plan to use the materials in meetings with investors, analysts, and other parties from time to time. This is an informational update with no transaction terms or financial results disclosed in the notice.
Larimar Therapeutics, Inc. (LRMR) filed an 8-K to report a material event: a press release and conference presentation dated September 29, 2025 announcing positive clinical data from its ongoing long‑term open‑label study of nomlabofusp in participants with Friedreich's ataxia. The filing cites positive results at the 25 mg and 50 mg daily subcutaneous dose levels given either by self‑administration or by a caregiver. The press release and presentation are attached as Exhibit 99.1. The filing text is brief and does not disclose detailed efficacy endpoints, participant counts, statistical results, safety findings, or next regulatory steps.